Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This study will examine an investigational (experimental) treatment using gemcitabine,
cisplatin, and celecoxib. Preliminary studies have shown that this experimental treatment may
be effective in reducing the size of cancerous tumors and/or preventing further tumor growth.
This is a phase II clinical trial studying the reactions of the patient's body and their
tumor to the combination of gemcitabine, cisplatin, and celecoxib. The purpose of this study
is to see if the tumor responds to this treatment and to determine how long the response
lasts. This study will also look at what kind of side effects this experimental treatment
causes and see how often these side effects occur. Blood levels of celecoxib will be measured
to find out how this treatment affects factors (proteins) involved in new blood vessel
formation and tumor growth (angiogenesis).
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center
Collaborators:
Barbara Ann Karmanos Cancer Institute Eli Lilly and Company